Lilly has entered into a definitive agreement to acquire Orna Therapeutics in a deal valued at approximately US$2.4 B. This acquisition will provide Lilly with access to Orna’s pipeline of innovative cell therapies targeting B cell-driven autoimmune diseases, including its lead asset ORN‑252, a CD19 targeting CAR-T therapy. The move aligns with Lilly’s strategic emphasis on advancing novel treatments within autoimmune disease areas as Orna’s technology offers the potential for sustained therapeutic protein expression compared to conventional RNA or cell therapy platforms, supporting the development of treatments not previously feasible.